Roblegg E - Search Results

1

Evaluation of a physiological in vitro system to study the transport of nanoparticles through the buccal mucosa.

Roblegg E, Fröhlich E, Meindl C, Teubl B, Zaversky M, Zimmer A. Roblegg E, et al. Nanotoxicology. 2012 Jun;6(4):399-413. doi: 10.3109/17435390.2011.580863. Epub 2011 May 18. Nanotoxicology. 2012. PMID: 21591874

2

Development of a Workflow to Engineer Tailored Microparticles Via Inkjet Printing.

Winter C, Zettl M, Mantanus J, Hadjittofis E, Leitinger G, Kolb D, Hsiao WK, Spoerk M, Paudel A, Roblegg E, Pinto JT. Winter C, et al. Among authors: roblegg e. Pharm Res. 2023 Jan;40(1):281-294. doi: 10.1007/s11095-022-03426-4. Epub 2022 Nov 15. Pharm Res. 2023. PMID: 36380170

3

Cytotoxicity of nanoparticles independent from oxidative stress.

Fröhlich E, Samberger C, Kueznik T, Absenger M, Roblegg E, Zimmer A, Pieber TR. Fröhlich E, et al. Among authors: roblegg e. J Toxicol Sci. 2009 Oct;34(4):363-75. doi: 10.2131/jts.34.363. J Toxicol Sci. 2009. PMID: 19652459 Free article.

4

Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes.

Fröhlich E, Kueznik T, Samberger C, Roblegg E, Wrighton C, Pieber TR. Fröhlich E, et al. Among authors: roblegg e. Toxicol Appl Pharmacol. 2010 Feb 1;242(3):326-32. doi: 10.1016/j.taap.2009.11.002. Epub 2009 Nov 10. Toxicol Appl Pharmacol. 2010. PMID: 19909766

5

Development of lipophilic calcium stearate pellets using ibuprofen as model drug.

Roblegg E, Ulbing S, Zeissmann S, Zimmer A. Roblegg E, et al. Eur J Pharm Biopharm. 2010 May;75(1):56-62. doi: 10.1016/j.ejpb.2010.01.005. Epub 2010 Jan 18. Eur J Pharm Biopharm. 2010. PMID: 20080179

6

Reformulation of a codeine phosphate liquid controlled-release product.

Roblegg E, Dittrich P, Haltmeyer K, Zimmer A. Roblegg E, et al. Drug Dev Ind Pharm. 2010 Dec;36(12):1454-62. doi: 10.3109/03639045.2010.487870. Epub 2010 Jun 10. Drug Dev Ind Pharm. 2010. PMID: 20533890

7

Pharmacokinetics of a novel liquid controlled release codeine formulation.

Dittrich P, Beubler E, Haltmeyer K, Zimmer A, Roblegg E. Dittrich P, et al. Among authors: roblegg e. Drug Dev Ind Pharm. 2011 Sep;37(9):1119-24. doi: 10.3109/03639045.2011.561351. Epub 2011 Mar 21. Drug Dev Ind Pharm. 2011. PMID: 21417617 Clinical Trial.

8

Use of the direct compression aid Ludiflash(®) for the preparation of pellets via wet extrusion/spheronization.

Roblegg E, Schrank S, Griesbacher M, Radl S, Zimmer A, Khinast J. Roblegg E, et al. Drug Dev Ind Pharm. 2011 Oct;37(10):1231-43. doi: 10.3109/03639045.2011.566271. Epub 2011 Mar 25. Drug Dev Ind Pharm. 2011. PMID: 21438702

9

Cytotoxity of nanoparticles is influenced by size, proliferation and embryonic origin of the cells used for testing.

Fröhlich E, Meindl C, Roblegg E, Griesbacher A, Pieber TR. Fröhlich E, et al. Among authors: roblegg e. Nanotoxicology. 2012 Jun;6(4):424-39. doi: 10.3109/17435390.2011.586478. Epub 2011 May 31. Nanotoxicology. 2012. PMID: 21627401

10

Development of sustained-release lipophilic calcium stearate pellets via hot melt extrusion.

Roblegg E, Jäger E, Hodzic A, Koscher G, Mohr S, Zimmer A, Khinast J. Roblegg E, et al. Eur J Pharm Biopharm. 2011 Nov;79(3):635-45. doi: 10.1016/j.ejpb.2011.07.004. Epub 2011 Jul 27. Eur J Pharm Biopharm. 2011. PMID: 21801834

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters